Influenza vaccine

Adult: As inactivated or recombinant influenza vaccine: 0.5 mL for 1 dose via IM inj (preferably in the deltoid muscle) or deep SC inj. Vaccine content, route of administration and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Child: As inactivated influenza vaccine: 6-35 months 0.25 mL or 0.5 mL; ≥36 months 0.5 mL. In patients 6 months to <9 years of age who have not been previously vaccinated against influenza, give a 2nd dose after at least 4 weeks. Doses are given via IM inj in the anterolateral aspect of the thigh (young children) or deltoid muscle of the upper arm (older children) or deep SC inj. Vaccine content, route of administration, approved ages and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).

Adult: As live attenuated influenza vaccine: ≤49 years 0.2 mL for 1 dose, to be given as 0.1 mL per nostril. Vaccine content, approved ages and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Child: As live attenuated influenza vaccine: 2-17 years 0.2 mL, to be given as 0.1 mL per nostril. In patients <9 years of age who have not been previously vaccinated against influenza, give a 2nd dose after at least 4 weeks. Vaccine content, approved ages and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).